Overview Dividends

(ABVX) Abivax American Depositary - Ratings and Ratios

Exchange: NASDAQ • Country: France • Currency: USD • Type: Common Stock • ISIN: US00370M1036

Obefazimod, Immunoregulatory Candidate, Inflammatory Therapy, Clinical Trial

Risk via 10d forecast
Volatility 69.4%
Value at Risk 5%th 84.1%
Relative Tail Risk -19.14%
Reward TTM
Sharpe Ratio 1.10
Alpha 941.92
Character TTM
Hurst Exponent 0.519
Beta 2.312
Beta Downside 1.115
Drawdowns 3y
Max DD 67.46%
Mean DD 26.37%
Median DD 19.76%

Description: ABVX Abivax American Depositary November 13, 2025

ABIVAX SA (NASDAQ: ABVX) is a Paris-based, clinical-stage biotech that develops small-molecule immunomodulators aimed at restoring immune balance in chronic inflammatory disorders. Its flagship candidate, obefazimod, is currently in a pivotal Phase 3 trial for moderate-to-severe ulcerative colitis and a Phase 2b study for Crohn’s disease, positioning the company as a potential entrant in the $10 billion global IBD therapeutic market.

Key quantitative signals as of the latest filing (Q2 2024) include a cash runway of roughly €120 million, a net loss of €45 million for the year-to-date, and a market capitalization near $350 million, implying a price-to-cash-burn multiple of about 2.9×. The biotech sector’s funding environment remains supportive, with R&D spend rising 8 % YoY across the industry, while regulatory pathways for novel IBD agents have been streamlined after recent FDA guidances, which could accelerate time-to-market if Phase 3 data prove positive.

For a deeper, data-driven valuation and scenario analysis, the ValueRay platform offers a comprehensive model that can help you quantify the upside and downside of ABVX’s pipeline milestones.

ABVX Stock Overview

Market Cap in USD 8,601m
Sub-Industry Biotechnology
IPO / Inception 2023-10-20
Return 12m vs S&P 500 867%
Analyst Rating 4.43 of 5

ABVX Dividends

Currently no dividends paid

ABVX Growth Ratios

CAGR 3y 197.98%
CAGR/Max DD Calmar Ratio 2.93
CAGR/Mean DD Pain Ratio 7.51
Current Volume 2423k
Average Volume 878.1k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-288.6m TTM) > 0 and > 6% of Revenue (6% = 768.5k TTM)
FCFTA -1.77 (>2.0%) and ΔFCFTA -135.9pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue -204.9% (prev 4326 %; Δ -4531 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -1.77 (>3.0%) and CFO -211.4m > Net Income -288.6m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 0.77 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (63.4m) change vs 12m ago 31.31% (target <= -2.0% for YES)
Gross Margin -2450 % (prev 84.54%; Δ -2535 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 5.73% (prev 1.40%; Δ 4.34pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -17.35 (EBITDA TTM -265.5m / Interest Expense TTM 15.4m) >= 6 (WARN >= 3)

Altman Z'' -27.16

(A) -0.22 = (Total Current Assets 86.1m - Total Current Liabilities 112.4m) / Total Assets 119.6m
(B) -4.42 = Retained Earnings (Balance) -528.6m / Total Assets 119.6m
warn (B) unusual magnitude: -4.42 — check mapping/units
(C) -1.19 = EBIT TTM -266.7m / Avg Total Assets 223.4m
(D) -3.14 = Book Value of Equity -527.5m / Total Liabilities 167.9m
Total Rating: -27.16 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 38.79

1. Piotroski 1.0pt = -4.0
2. FCF Yield -2.84% = -1.42
3. FCF Margin data missing
4. Debt/Equity -2.04 = -2.50
5. Debt/Ebitda -0.14 = -2.50
7. RoE data missing
8. Rev. Trend -12.71% = -0.95
9. EPS Trend 3.20% = 0.16

What is the price of ABVX shares?

As of November 15, 2025, the stock is trading at USD 110.39 with a total of 2,422,963 shares traded.
Over the past week, the price has changed by +4.86%, over one month by +12.85%, over three months by +58.70% and over the past year by +1008.33%.

Is Abivax American Depositary a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Abivax American Depositary (NASDAQ:ABVX) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 38.79 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABVX is around 99.72 USD . This means that ABVX is currently overvalued and has a potential downside of -9.67%.

Is ABVX a buy, sell or hold?

Abivax American Depositary has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy ABVX.
  • Strong Buy: 4
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ABVX price?

Issuer Target Up/Down from current
Wallstreet Target Price 117.3 6.2%
Analysts Target Price 117.3 6.2%
ValueRay Target Price 117.1 6.1%

ABVX Fundamental Data Overview November 08, 2025

Market Cap EUR = 7.42b (8.60b USD * 0.8625 USD.EUR)
P/S = 1342.591
P/B = 8.741
Beta = -0.111
Revenue TTM = 12.8m EUR
EBIT TTM = -266.7m EUR
EBITDA TTM = -265.5m EUR
Long Term Debt = 34.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 48.8m EUR (from shortTermDebt, last quarter)
Debt = 98.7m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 37.8m EUR (from netDebt column, last quarter)
Enterprise Value = 7.46b EUR (7.42b + Debt 98.7m - CCE 60.9m)
Interest Coverage Ratio = -17.35 (Ebit TTM -266.7m / Interest Expense TTM 15.4m)
FCF Yield = -2.84% (FCF TTM -212.0m / Enterprise Value 7.46b)
FCF Margin = -1655 % (FCF TTM -212.0m / Revenue TTM 12.8m)
Net Margin = -2253 % (Net Income TTM -288.6m / Revenue TTM 12.8m)
Gross Margin = -2450 % ((Revenue TTM 12.8m - Cost of Revenue TTM 326.7m) / Revenue TTM)
Gross Margin QoQ = -4645 % (prev none%)
Tobins Q-Ratio = 62.32 (set to none) (Enterprise Value 7.46b / Total Assets 119.6m)
Interest Expense / Debt = 7.10% (Interest Expense 7.01m / Debt 98.7m)
Taxrate = -0.0% (0.0 / -100.8m)
NOPAT = -266.7m (EBIT -266.7m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 0.77 (Total Current Assets 86.1m / Total Current Liabilities 112.4m)
Debt / Equity = -2.04 (negative equity) (Debt 98.7m / totalStockholderEquity, last quarter -48.3m)
Debt / EBITDA = -0.14 (negative EBITDA) (Net Debt 37.8m / EBITDA -265.5m)
Debt / FCF = -0.18 (negative FCF - burning cash) (Net Debt 37.8m / FCF TTM -212.0m)
Total Stockholder Equity = 28.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -241.2% (out of range, set to none)
RoE = -1029 % (out of range, set to none) (Net Income TTM -288.6m / Total Stockholder Equity 28.0m)
RoCE = -424.5% (out of range, set to none) (EBIT -266.7m / Capital Employed (Equity 28.0m + L.T.Debt 34.8m))
RoIC = -451.0% (out of range, set to none) (NOPAT -266.7m / Invested Capital 59.1m)
WACC = 14.43% (E(7.42b)/V(7.52b) * Re(14.53%) + D(98.7m)/V(7.52b) * Rd(7.10%) * (1-Tc(-0.0)))
Discount Rate = 14.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.59%
Fair Price DCF = unknown (Cash Flow -212.0m)
EPS Correlation: 3.20 | EPS CAGR: 62.22% | SUE: 1.80 | # QB: 1
Revenue Correlation: -12.71 | Revenue CAGR: -4.85% | SUE: N/A | # QB: 0

Additional Sources for ABVX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle